Dopamine D3 Receptors Mediate the Discriminative Stimulus Effects of Quinpirole in Free-Feeding Rats

Michelle G. Baladi, Amy H. Newman, and Charles P. France

Departments of Pharmacology (M.G.B., C.P.F.) and Psychiatry (C.P.F.), the University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Medicinal Chemistry Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, Maryland (A.H.N.)

Received June 30, 2009; accepted September 30, 2009

ABSTRACT

The discriminative stimulus effects of dopamine (DA) D3/D2 receptor agonists are thought to be mediated by D2 receptors. To maintain responding, access to food is often restricted, which can alter neurochemical and behavioral effects of drugs acting on DA systems. This study established stimulus control with quinpirole in free-feeding rats and tested the ability of agonists to mimic and antagonists to attenuate the effects of quinpirole. The same antagonists were studied for their ability to attenuate quinpirole-induced yawning and hypothermia. DA receptor agonists apomorphine and lisuride, but not amphetamine and morphine, occasioned responding on the quinpirole lever. The discriminative stimulus effects of quinpirole were attenuated by the D3 receptor-selective antagonist N-[(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]-trans-but-2-enyl)-4-pyridine-2-yl]-benzamide HCl (PG01037) and the nonselective D3/D2 receptor antagonist raclopride, but not by the D2 receptor-selective antagonist 3-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]methyl-1H-indole (L-741,626); the potencies of PG01037 and raclopride to antagonize this effect of quinpirole paralleled their potencies to antagonize the ascending limb of the quinpirole yawning dose-response curve (thought to be mediated by D3 receptors). L-741,626 selectively antagonized the descending limb of the quinpirole yawning dose-response curve, and both L-741,626 and raclopride, but not PG01037, antagonized the hypothermic effects of quinpirole (thought to be mediated by D2 receptors). Food restriction (10 g/day/7 days) significantly decreased quinpirole-induced yawning without affecting the quinpirole discrimination. Many discrimination studies on DA receptor agonists use food-restricted rats; together with those studies, the current experiment using free-feeding rats suggests that feeding conditions affecting the behavioral effects of direct-acting DA receptor agonists might also have an impact on the effects of indirect-acting agonists such as cocaine and amphetamine.

Many drugs of abuse as well as many drugs used in the clinic have actions on dopamine (DA) systems; however, there are a number of different DA receptors [i.e., D1-like (D1 and D5) and D2-like (D2, D3, and D4)], and the relative contribution of each receptor subtype to the abuse or therapeutic effects of drugs is not known. For example, DA D3 and D2 receptors are thought to mediate many of the behavioral effects of cocaine because some D3/D2 receptor agonists share behavior (e.g., discriminative stimulus) effects with cocaine (Caine and Koob, 1993; Acrit et al., 1995; Spealman, 1996; Sinnott et al., 1999). Drug discrimination procedures have been used extensively to investigate the role of different DA receptors, particularly D3 and D2, in mediating the behavioral effects of drugs such as cocaine that act indirectly through DA receptors. Collectively, studies conducted with rats suggest that the discriminative stimulus effects of a number of DA receptor agonists that bind to both D3 and D2 receptors are mediated through D2 receptors (Appel et al., 1988; Kleven and Koek, 1997; Bristow et al., 1998; Baker et al., 1999; Katz and Alling, 2000; Millan et al., 2000, 2007; Christian et al., 2001; Koffarnus et al., 2009). For example, the discriminative stimulus effects of the D3/D2 receptor agonist S32504 are antagonized by the D2 receptor-selective antagonist L-741,626 but not by the D3 receptor-
selective antagonist S33084 (Millan et al., 2007), suggesting
that the selective binding of S32504 to D3 receptors
does not correlate with receptors mediating its discriminative
stimulus effects. Moreover, the discriminative stimulus
effects of the D3/D2 receptor agonist (+)-PD 128,907 are
antagonized by the D2 receptor-selective antagonist L-741,626 and not by the D3 receptor-selective antagonist
GR 103,691 (Bristow et al., 1998).

Most drug discrimination studies with DA receptor ago-
nists in rats used food to maintain responding, thereby ne-
cessitating food restriction throughout the experiment. How-
ever, it is becoming clear that restricting access to food can
change the behavioral and neurochemical effects of many
drugs, including drugs acting on DA systems. For example,
food restriction decreases extracellular DA (Pothos et al.,
1995), increases D2 receptor binding (Thanos et al., 2008),
and increases coupling between DA receptors and G proteins
(Carr et al., 2003). Food restriction also decreases the sensi-
tivity of rats to yawning induced by DA receptor agonists
including quinpirole and pramipexole (Collins et al., 2008;
Sevak et al., 2008; Baladi and France, 2009). DA receptor
agonist-induced yawning generates an inverted U-shaped
dose-response curve, with the ascending limb thought to be
mediated by D3 receptors and the descending limb by D2
receptors, and the decreased sensitivity to agonist-induced
yawning in food-restricted rats is thought to be due to in-
creased sensitivity of D2 receptors (Collins et al., 2008).
Although the discriminative stimulus effects of pramipexole
are thought to be mediated by D2, but not D3, receptors
(Koffarnus et al., 2009), it is unclear whether food restriction
that modifies some effects of DA receptor agonists (e.g.,
yawning) also modifies the discriminative stimulus effects of
DA receptor agonists.

In this study, stimulus control was established with the
DA receptor agonist quinpirole in free-feeding rats respond-
ing under a schedule of shock avoidance. DA receptor ago-
nists were studied for their ability to mimic the quinpirole
discriminative stimulus, and DA receptor antagonists were
studied for their ability to attenuate the quinpirole discrimi-
native stimulus. The antagonists studied vary in selectivity
for different DA receptor subtypes as follows: the D2 recep-
tor-selective antagonist L-741,626 [15-fold selective for D2
over D3 receptors in vitro (Grundt et al., 2007a)], the D3
receptor-selective antagonist PG01037 [133-fold selective for
D3 over D2 receptors in vitro (Grundt et al., 2005, 2007b)],
and the nonselective D3/D2 receptor antagonist raclopride.
The same antagonists were also studied for their ability to
attenuate quinpirole-induced yawning (presumably the as-
cending limb reflecting activity at D3 receptors and descend-
ing limb reflecting activity at D2 receptors) and quinpirole-
induced hypothermia (thought to be mediated by D2 receptors).
Finally, feeding conditions that decrease DA ago-
nist-induced yawning were examined to see whether the
discriminative stimulus effects of quinpirole were similarly
decreased by food restriction. It was expected that the dis-
criminative stimulus effects of quinpirole in free-feeding rats,
previously lacking increased D2 receptor sensitivity that
occurs during ongoing food restriction, would be mediated by
D3 receptors or by a combination of D3 and D2 receptors,
and, to the extent that food restriction selectively increases
sensitivity of D2 receptors, it was expected that the D3 re-
ceptor-mediated discriminative stimulus effects of quinpirole
would not be affected by food restriction.

Materials and Methods

Subjects. Fourteen male Sprague-Dawley rats (Harlan, Indiana-
polis, IN), weighing 250 to 300 g upon arrival, were housed indi-
vividually in an environmentally controlled room (24 ± 1°C, 50 ± 10%
relative humidity) under a 12-h light/dark cycle. Six rats were used
in a discrimination study, and eight rats were used in a study on
yawning and body temperature. All rats had unlimited access to
standard laboratory chow and water, except during experimental
sessions (for all rats) and on two occasions when rats in the drug
discrimination study were restricted to 10 g/day of food for 7 days.
Animals were maintained and experiments were conducted in accord-
ance with the Institutional Animal Care and Use Committee, the
University of Texas Health Science Center at San Antonio, and with
the Guide for Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, 1996).

Apparatus. Experimental sessions were conducted in sound-at-
tenuating, ventilated enclosures (models ENV-018ME and ENV-
008CT; Med Associates Inc., St. Albans, VT), which contained an
operant chamber. One side of the chamber was a stainless steel
response panel equipped with two metal levers and stimulus lights
11.5 cm apart and separated by a clear Plexiglas partition (1.4 ×
5.2 × 20.4 cm high) that extended from the floor to the ceiling of the
chamber. The grid floor of the chamber was 19 stainless steel rods,
4.8 mm in diameter, spaced 1.6 cm apart, and oriented parallel to the
response panel. A constant current generator (Med Associates, Inc.)
delivered a scrambled electric current to the grid floor of the cham-
ber. Data were collected using MED-PC IV software (Med Associates,
Inc.) and a PC interface.

Drug Discrimination. Six rats were trained to discriminate
0.032 mg/kg quinpirole (intraperitoneal) from vehicle (i.e., saline)
under a schedule of stimulus shock termination. Discriminative con-
trol was first established with an acute-dosing, single-cycle proce-
dure that consisted of 21 trials and began with a 10-min timeout
period, during which stimulus lights were not illuminated and re-
sponding had no programmed consequence. The timeout period
was followed by illumination of a house light that signaled the delivery of
a brief (250 ms) shock stimulus (1.5 mA) every 10 s; a response on the
injection-appropriate (correct) lever or the passage of 50 s turned off
the house light, ended the trial, and initiated a 50-s timeout. Vehicle
or 0.032 mg/kg quinpirole was administered immediately before the
session. Stimulus control was considered adequate for testing when the
following criteria were satisfied for four consecutive or five of six
sessions: 1) the first response of the cycle was made on the correct
lever and 2) at least 80% of the trials were completed by a response on
the correct lever. Test sessions were identical to training sessions
except that a response on either lever postponed shock and different
doses of quinpirole were administered before the session. After a
quinpirole dose-response curve was determined under the single-
cycle procedure, the experimental conditions were changed to a cu-
mulative-dosing, multiple-cycle procedure consisting of one to four
20-min cycles. Each cycle consisted of 10 trials and began with a
10-min timeout period, during which stimulus lights were not illu-
minated, and responding had no programmed consequence. The
timeout period was followed by illumination of the house light sig-
aling scheduled delivery of a brief electric stimulus every 10 s; a
response on the injection-appropriate (correct) lever or the passage of
30 s turned off the house light, ended the trial, and initiated a 30-s
timeout. If fewer than five trials were completed by a response on the
correct lever in any cycle, the session ended. For vehicle training
sessions, animals received an intraperitoneal injection of vehicle
before one cycle followed by between one and three sham (no injec-
tion) cycles. For drug training sessions, animals received an in-
traperitoneal injection of 0.032 mg/kg quinpirole before one cycle fol-
lowed by a single sham injection. The cycle during which quinpirole
was administered was preceded by zero to two cycles during which vehicle or sham injections were administered. Testing resumed after animals satisfied the following criteria for four consecutive or five of six sessions under the multiple-cycle procedure: 1) the first response of all cycles was on the correct lever and 2) at least 80% of the trials were completed by a response on the correct lever. Thereafter, tests were conducted whenever animals satisfied these same criteria for two consecutive sessions. Multiple-cycle test sessions were identical to training sessions except that a response on either lever postponed shock and either vehicle or increasing doses of drug were administered across cycles. For substitution studies, vehicle was administered before the first cycle, followed by increasing doses of drug before subsequent cycles, with the cumulative dose increasing by 0.5 log unit per cycle. Drugs were studied up to doses that occasioned greater than 80% responding on the quinpirole lever. For drug combination studies, a single dose of antagonist was administered (subcutaneously) 10 min before the first (saline) test cycle (i.e., 30 min before the first dose of quinpirole).

To test whether food restriction alters the discriminative stimulus effects of quinpirole, dose-response curves were determined for quinpirole the day before and the day after a 7-day period when training was suspended and rats continued to have unlimited access to food in the home cage. The similarity in ED50 values of these two dose-response curves (mean [95% CL] = 0.016 [0.013–0.018] mg/kg before and ED50 = 0.018 [0.015–0.021] mg/kg after) demonstrated that suspension of training did not adversely affect stimulus control with quinpirole. Next quinpirole discrimination dose-response curves were determined the day before and the day after a 7-day period when training was suspended and rats received only 10 g/day of food in the home cage. On different occasions, dose-response curves for quinpirole-induced yawning were determined (see below) in the rats used in the discrimination study: once when they had unlimited access to food and once when they received 10 g/day of food for 7 days (no discrimination studies were conducted during these yawning studies).

Yawning. Yawning was defined as an opening of the mouth such that the lower incisors were completely visible (Kurashima et al., 1995; Sevak et al., 2008; Baladi and France, 2009). On the day of testing, rats were transferred from their home cage to a test cage (same dimensions as the home cage but with no food, water, or bedding) and allowed to habituate for 15 min. Cumulative dose-response curves were generated for quinpirole (0.003–2.0 mg/kg i.p.) with increasing doses administered every 30 min. Beginning 20 min after each injection, the total number of yawns was recorded for 10 min.

The six rats in the discrimination study were studied twice, once when they had unlimited access to food and once when they received 10 g/day of food for 7 days. A separate group of eight free-feeding rats were studied with cumulative doses of quinpirole alone and in combination with several different DA receptor antagonists: the D3 receptor-selective antagonist PG01037 (25.2 and 56.0 mg/kg s.c.), the D2 receptor-selective antagonist L-741,626 (1.0 and 3.2 mg/kg s.c.), and the nonselective D3/D2 receptor antagonist raclopride (0.032 and 0.056 mg/kg s.c.). The doses of L-741,626, PG01037, and raclopride were shown by others to have antagonist actions at dopamine receptors (Collins et al., 2005; Sevak et al., 2007). Antagonists were administered 30 min before administration of the first dose of quinpirole. Experimental sessions were separated by at least 48 h.

Body Temperature. In the same eight free-feeding rats that were studied for quinpirole-induced yawning, body temperature was measured in a temperature-controlled room (24 ± 1°C and 50 ± 10% relative humidity) by inserting a lubricated thermal probe (attached to a thermometer) 3 cm into the rectum. Animals were adapted to the experimental procedure by measuring body temperature on multiple occasions before drug administration commenced. Body temperature was measured during yawning experiments, after completion of each 10-min observation period and before the next injection.

Data Analyses. Drug discrimination data are expressed as a percentage of the total responses made on the quinpirole-associated lever averaged among six rats (±S.E.M.) and are plotted as a function of dose. Also plotted as a function of dose is the percentage of trials completed (±S.E.M.). When a rat completed fewer than five trials, discrimination data from that test were not included in the average, although data for the percentage of trials completed were included in the group average. Yawing data were expressed as the average (±S.E.M.) number of yawns during the 10-min observation period and plotted as a function of dose. Body temperature data are expressed as a change in degrees Centigrade from baseline (i.e., body temperature determined after vehicle administration) averaged among eight rats (±S.E.M.) and plotted as a function of dose.

A two-way repeated-measures analysis of variance with quinpirole dose and feeding condition as factors was used to determine whether yawning was different in the same group of rats before and during food restriction; post hoc multiple comparisons were made with the Bonferroni test. For each group, differences between quinpirole dose-response curves in the presence and absence of antagonist were analyzed by simultaneously fitting straight lines to the linear portion of the dose-response curves by means of GraphPad Prism (GraphPad Software Inc., San Diego, CA). The linear portion included doses that spanned the 50% level of effect and included not more than one dose with greater than 75% effect and not more than one dose with less than 25% effect. Differences between slopes and intercepts of the curves were analyzed with the F ratio test (GraphPad Prism), as detailed elsewhere (Koek et al., 2006). ED50 values were calculated for individual rats using linear regression when at least three appropriate data points were available and otherwise by interpolation. To calculate ED50 values for quinpirole-induced yawning and hypothermia in the absence and presence of antagonists, a common maximum effect was selected for individual rats. The 95% CIs were calculated from ED50 values averaged among rats. To evaluate changes in potency as a result of antagonist treatment, a dose ratio was calculated for each rat by dividing the ED50 obtained in the presence of antagonist by the ED50 value obtained in the absence of antagonist. When the 95% CIs of the dose ratio did not include 1, antagonists were considered to significantly change the potency of the drug relative to its potency in the absence of antagonist.

Drugs. The following compounds were purchased from Sigma-Aldrich (St. Louis, MO): (--)-quinpirole [(trans-)-(4R)-4,4a,5,6,7,8,9-octahydro-5-propyl-1H-pyrazolo[3,4-g]quinoline HCl]; S(+)-raclopride [(+) tartrate salt (5,5-dichloro-N-(1-amino- 2,3-dichlorophenyl)-piperazine-1-yl)-but-2-enyl]-(+)-pyridine-2-yl-benzamide; and S(+)-1-amphetamine hydrochloride. Lisuride hydrochloride maleate was purchased from Alfarma Research and Development (Prague, Czech Republic), and L-741,626 was purchased from Tocris Bio-science (Ellisville, MO). Morphine sulfate and d-amphetamine sulfate were provided by the Research Technology Branch, National Institute of Drug Abuse (Rockville, MD). PG01037-N(4-[4-(2,3-dichlorophenyl)-piperazin-1-yl)-trans-but-2- enyl]-4-pyridine-2-yl-benzamide HCl) was synthesized by Jianjing Cao (Medicinal Chemistry Section, National Institute on Drug Abuse, Baltimore, MD) using methods reported previously (Grundt et al., 2005). The vehicle for all drugs was sterile 0.9% saline with the exceptions of L-741,626 (dissolved in 5% ethanol with 1 M HCl) and PG01037 (dissolved in 10% β-cyclodextrin). L-741,626, PG01037, and raclopride were administered subcutaneously, typically in a volume of 1 ml/kg; other drugs were administered intraperitoneally in a volume of 1 ml/kg.

Results

Rats satisfied the testing criteria under the single-cycle procedure after an average of 32 ± 5 (mean ± S.E.M.) train-
ing sessions (range = 19 to 51). Conditions were changed to a multiple-cycle procedure, and rats satisfied the testing criteria again after an average of 15 ± 6 (range = 6 to 42) training sessions. Vehicle (Fig. 1, top panel, data above V) and small doses of quinpirole occasioned responding predominantly on the vehicle-associated lever, whereas larger doses of quinpirole increased responding on the quinpirole-associated lever [mean ED50 = 0.015 (95% CL 0.012–0.018)] (Fig. 1, top panel). Lisuride and apomorphine also increased responding on the quinpirole-associated lever in a dose-related manner (Fig. 1, top panel) with the largest dose of each occasioning more than 80% drug-lever responding [lisuride ED50 = 0.004 mg/kg (0.001–0.012) and apomorphine ED50 = 0.090 mg/kg (0.017–0.164)]. Quinpirole, lisuride, and apomorphine did not markedly alter the percentage of trials completed (Fig. 1, bottom panel). Amphetamine and morphine did not occasion responding on the quinpirole-associated lever up to doses of each that markedly decreased the percentage of trials completed (Fig. 1).

At doses of 1.0 and 3.2 mg/kg, L-741,626 did not clearly alter the discriminative stimulus effects of quinpirole (Fig. 2, top panel). In contrast, PG01037 (32 and 56 mg/kg) and raclopride (0.032 and 0.056 mg/kg) antagonized the discriminative stimulus effects of quinpirole, in each case shifting the dose-response curve to the right in a dose-related manner (Fig. 2, middle and bottom panels, respectively). Under control conditions, a dose of 0.032 mg/kg quinpirole occasioned greater than 80% drug-lever responding; in the presence of PG01037 or raclopride, a 3-fold larger dose of quinpirole (0.1 mg/kg) was required to obtain greater than 80% drug-lever responding. When administered alone, none of the antagonists produced responding on the quinpirole lever (Fig. 2, data above V) or markedly altered the percentage of trials completed (data not shown).

Increasing doses of quinpirole first increased then decreased yawning, resulting in an inverted U-shaped dose-response curve (Fig. 3, all panels, ●). A dose of 1.0 mg/kg L-741,626 shifted the descending, but not the ascending, limb of the yawning dose-response curve to the right (Fig. 3, top panel, compare ● with □). A larger dose of L-741,626 (3.2 mg/kg) shifted both limbs of the yawning dose-response curve to the right (Fig. 3, top panel). A dose of 32.0 or 56.0 mg/kg PG01037 shifted the ascending, but not the descending, limb of the yawning dose-response curve to the right (Fig. 3, middle panel, compare ● with □ and △). Finally, doses of 0.032 or 0.056 mg/kg raclopride shifted both the ascending and descending limbs of the quinpirole yawning dose-response curve to the right (Fig. 3, bottom panel). When administered alone, none of the antagonists produced yawning (Fig. 3, data above V).

The same data shown in Figs. 2 and 3 are presented in Table 1 as dose ratios expressing the magnitude of shift to the right in the quinpirole discrimination and yawning dose-response curves. A dose of L-741,626 (1.0 mg/kg) that antagonized the descending limb of the quinpirole yawning dose-

![Fig. 1. Discriminative stimulus effects and the percentage of trials completed for lisuride, quinpirole, apomorphine, amphetamine, and morphine in six rats with unlimited access to food and discriminating 0.032 mg/kg quinpirole. Abscissa, dose in milligrams per kilogram of body weight; V, vehicle. Ordinates, mean (±S.E.M.) percentage of responses on the quinpirole lever (top) and mean (±S.E.M.) percentage of trials completed (bottom).](image1)

![Fig. 2. Discriminative stimulus effects of quinpirole administered alone (●) and in combination with different doses of L-741,626 (top), PG01037 (middle), and raclopride (bottom). See legend to Fig. 1 for other details.](image2)

![Fig. 3. Dose-response curves for quinpirole, L-741,626, PG01037, and raclopride for depression and yawning. Abscissa, dose in milligrams per kilogram of body weight; V, vehicle. Ordinates, mean (±S.E.M.) percentage of responses on the quinpirole lever (top) and mean (±S.E.M.) percentage of trials completed (bottom).](image3)
response curve did not significantly affect the discriminative stimulus effects of quinpirole or the ascending limb of the yawning dose-response curve. In contrast, doses of PG01037 that antagonized the discriminative stimulus effects of quinpirole and the ascending limb of the yawning dose-response curve did not significantly affect the descending limb of the yawning dose-response curve (Table 1). The same doses of raclopride antagonized the discriminative stimulus effects and both limbs of the yawning dose-response curve.

Quinpirole dose dependently decreased body temperature (Fig. 4, all panels, ●). L-741,626 and raclopride, but not PG01037, antagonized the hypothermic effects of quinpirole (Fig. 4). For example, 1.0 and 3.2 mg/kg L-741,626 shifted the quinpirole dose-response curve for hypothermia 2.26- and 2.81-fold to the right, respectively, and 0.032 and 0.056

![Fig. 3. Quinpirole-induced yawning when quinpirole was administered alone (●) and in combination with different doses of L-741,626 (top), PG01037 (middle), and raclopride (bottom) in eight rats with unlimited access to food. Ordinate, mean (±S.E.M.) number of yawns in the 10-min observation period. See legend to Fig. 1 for other details.](image1)

![Fig. 4. Quinpirole-induced hypothermia when quinpirole was administered alone (●) and with different doses of L-741,626 (top), PG01037 (middle), and raclopride (bottom). Ordinate, mean (±S.E.M.) change in body temperature (degrees Centigrade). See legend to Fig. 1 for other details.](image2)

<table>
<thead>
<tr>
<th>TABLE 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antagonism of the discriminative stimulus effects and of yawning by quinpirole: dose ratios</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dose Ratio</th>
<th>Discrimination</th>
<th>Yawning (Ascending)</th>
<th>Yawning (Descending)</th>
</tr>
</thead>
<tbody>
<tr>
<td>L-741,626</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 mg/kg</td>
<td>1.55 (0.82–2.29)</td>
<td>1.71 (1.20–3.22)</td>
<td>3.64 (1.70–5.57)</td>
</tr>
<tr>
<td>3.2 mg/kg</td>
<td>1.25 (0.38–2.13)</td>
<td>1.14 (1.14–5.11)</td>
<td>2.96 (1.09–4.83)</td>
</tr>
<tr>
<td>PG01037</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>32 mg/kg</td>
<td>2.60 (1.58–3.62)</td>
<td>2.48 (1.82–3.68)</td>
<td>1.01 (0.67–1.35)</td>
</tr>
<tr>
<td>56 mg/kg</td>
<td>3.57 (2.85–4.28)</td>
<td>3.82 (2.23–5.41)</td>
<td>1.13 (0.96–1.27)</td>
</tr>
<tr>
<td>Raclopride</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.032 mg/kg</td>
<td>2.06 (1.15–2.96)</td>
<td>1.81 (1.10–2.52)</td>
<td>1.87 (1.33–2.77)</td>
</tr>
<tr>
<td>0.056 mg/kg</td>
<td>3.20 (1.80–4.60)</td>
<td>2.78 (1.30–3.81)</td>
<td>2.60 (1.23–3.93)</td>
</tr>
</tbody>
</table>

* Dose ratio (95% CL) for antagonizing the discriminative stimulus effects of quinpirole in six rats.
* Dose ratio (95% CL) for antagonizing the ascending limb of the quinpirole dose-response curve for yawning in eight rats.
* Dose ratio (95% CL) for antagonizing the descending limb of the quinpirole dose-response curve in eight rats.
* 95% CL does not include 1.
mg/kg raclopride shifted the quinpirole dose-response curve 2.50- and 3.60-fold to the right, respectively. Administration of the antagonists alone did not significantly change body temperature (data not shown).

Restricting rats to 10 g/day of food for 7 days significantly decreased ($P < 0.05$) sensitivity to quinpirole-induced yawning (Fig. 5, bottom panel) without affecting sensitivity to the discriminative stimulus effects of quinpirole (Fig. 5, top panel). When rats had unlimited access to food, the training dose of quinpirole (0.032 mg/kg) occasioned responding on the drug lever and maximally increased yawning (Fig. 5, ●). When rats were restricted to 10 g/day of food, the same dose of quinpirole continued to occasion responding on the drug lever but failed to significantly increase yawning (Fig. 5, △).

**Discussion**

The current study established stimulus control between 0.032 mg/kg quinpirole and vehicle in free-feeding rats responding under a two-choice, multiple-cycle, cumulative-dosing procedure. Others have established stimulus control with similar doses of quinpirole [0.03 mg/kg (Katz and Alling, 2000) and 0.025 mg/kg (Weathersby and Appel, 1986; Appel et al., 1988; Huffman et al., 1995)] and 0.03 mg/kg (Katz and Alling, 2000; Millan et al., 2000, 2007; Christian et al., 2001; Koffarnus et al., 2009) based on results of studies that used DA receptor antagonists to attenuate the effects of DA receptor agonists; however, most studies used food-restricted rats. In the current study, quinpirole dose-response curves were determined in the presence of different doses of antagonists that vary in their selectivity for D3 and D2 receptors. The D3 receptor-selective antagonist PG01037 and the nonspecific D3/D2 receptor antagonist raclopride, but not the D2 receptor-selective antagonist L-741,626, antagonized the discriminative stimulus effects of quinpirole in food-restricted rats, shifting the dose-response curve to the right. These data suggest that the discriminative stimulus effects of quinpirole in free-feeding rats are mediated predominantly, if not exclusively, by D3 receptors.

Yawning induced by DA receptor agonists yields an inverted U-shaped dose-response curve, and it is thought that the ascending limb of this curve (induction of yawning) is mediated by actions at D3 receptors and the descending limb (inhibition of yawning) is mediated by actions at D2 receptors (Collins et al., 2005). The same antagonists that were compared for their ability to antagonize the discriminative stimulus effects of quinpirole also were compared for their ability to antagonize quinpirole-induced yawning. The D3 receptor-selective antagonist PG01037 attenuated the ascending limb of the quinpirole dose-response curve in a dose-related manner without affecting the descending limb. In contrast, a dose of the D2 receptor-selective antagonist L-741,626 (1.0 mg/kg) that attenuated the descending limb of the quinpirole dose-response curve had no effect on the ascending limb. The nonselective D3/D2 receptor antagonist raclopride dose dependently attenuated both limbs of the dose-response curve for quinpirole-induced yawning. The ability of these antagonists to attenuate the discriminative stimulus effects of quinpirole in free-feeding rats parallels their ability to attenuate the ascending and, presumably, D3 receptor-mediated limb of the dose-response curve for quinpirole-induced yawning. In particular, the potencies of PG01037 and raclopride, but not of L-741,626, to antagonize the discriminative stimulus effects of quinpirole parallel their relative potencies in attenuating the ascending limb of the yawning dose-response curve (Table 1), further supporting the view that the discriminative stimulus effects of quin-
pirolo in free-feeding rats are mediated predominantly, if not exclusively, by D3 receptors.

Based on the effects of various DA receptor agonists administered alone and in combination with different DA receptor antagonists, it is thought that the hypothermic effects of D3/D2 receptor agonists (e.g., including quinpirole) are mediated by D2 receptors (Nunes et al., 1991; Chaperon et al., 2003; Collins et al., 2007). Consistent with that view, quinpirole-induced hypothermia was attenuated by the D2 receptor-selective antagonist L-741,626 and the nonselective D3/D2 receptor antagonist raclopride but not by the D3 receptor-selective antagonist PG01037.

Food restriction markedly decreases sensitivity of rats to quinpirole-induced yawning (Sevak et al., 2008; Baladi and France, 2009); interpretations of that observation might include decreased sensitivity of D3 receptors to agonists, increased sensitivity of D2 receptors to agonists, or both decreased sensitivity of D3 and increased sensitivity of D2 receptors. However, results of behavioral as well as molecular studies indicate that the effect of food restriction is to increase sensitivity of D2 receptors (Carr et al., 2003; Collins et al., 2008; Thanos et al., 2008). If the discriminative stimulus effects of DA receptor agonists in free-feeding rats are mediated by D2 receptors, then it might be expected that food restriction would increase sensitivity to those effects, as reflected by a leftward shift in the dose-response curve. However, food restriction (10 g/day for 7 days) that markedly decreased sensitivity to quinpirole-induced yawning had no effect on the discriminative stimulus effects of quinpirole in the same group of rats, supporting the hypothesis that D2 receptors are not involved in the discriminative stimulus effects of quinpirole in free-feeding rats. Food restriction in the current study reduced body weight to approximately 90% of free-feeding weight, somewhat less than body weight loss reported in other studies using food restriction and studying dopamine drugs (e.g., 80–85%; Weathersby and Appel, 1986; Carr et al., 2003; Collins et al., 2008; Koffarnus et al., 2009). Together with the current antagonism studies, these data support the view that D3 receptors mediate the discriminative stimulus effects of quinpirole in free-feeding rats and that sensitivity of D3 receptors to agonists is not markedly affected by food restriction. Future studies might include establishing a discrimination with a highly selective D2 receptor agonist in free-feeding rats (i.e., acute food restriction might shift the dose-response curve leftward) or with a highly selective D3 receptor agonist in food-restricted rats (i.e., D3 and not D2 receptor antagonists should block the training stimulus). Moreover, it is not clear whether the reinforcer used to maintain responding (i.e., shock) influences the contribution of different DA receptors in the discriminative stimulus effects of agonists.

In summary, although D2 receptors are thought to mediate the discriminative stimulus effects of quinpirole in food-restricted rats, D3 receptors seem to mediate the discriminative stimulus effects of quinpirole in free-feeding rats. Thus, feeding conditions can affect the contribution of D3 and D2 receptors to the discriminative stimulus effects of quinpirole. Several mechanisms are thought to underlie the effects of food restriction on DA receptors, including increased DA receptor number and signaling and reduced plasma levels of hormones such as insulin and leptin that can directly affect DA systems. Understanding the link between feeding condition and DA neurotransmission might be critical for understanding the comorbidity of eating disorders and drug abuse and also has implications for understanding how feeding condition might affect the behavioral effects of other drugs acting on DA systems, including drugs of abuse such as cocaine and amphetamine.

Acknowledgments

We acknowledge Jianjing Cao in the Medicinal Chemistry Section, National Institute on Drug Abuse-Intramural Research Program, for synthesizing the PG01037 used in this study.

References


Address correspondence to: Dr. Charles P. France, Department of Pharmacology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229-3900. E-mail: france@uthscsa.edu